drugset / Trial / NCT00216255
EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.
Timeline
- Start
- 2005-04
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pagoclone | Small molecule | 0.15 mg | — |
| Subject | Pagoclone | Small molecule | 0.3 mg | — |
| Subject | Pagoclone | Small molecule | 0.6 mg | — |